Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for aggressive lymphoma: drug MT-2111 under trial

NCT ID NCT05658562

Ongoing Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called MT-2111 (loncastuximab tesirine) in people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The trial has two parts: first, to find a safe dose, and second, to see if the drug can shrink tumors. It involves 46 participants in Japan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MT-2111 (loncastuximab tesirine), a drug given by IV infusion
What this could lead to
If successful, this could offer a new treatment option for patients with hard-to-treat DLBCL, potentially shrinking tumors or slowing disease progression.
What could go wrong
This is an early-phase trial with only 46 participants, so results may not apply broadly. The drug may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

  • Aso Iizuka Hospital

    Iizuka-shi, Fukuoka, 820-8505, Japan

  • Cancer Institute Hospital of JFCR

    Koto-ku, Tokyo, 135-0063, Japan

  • Disaster Medical Center

    Tachikawa-shi, Tokyo, 190-0014, Japan

  • Fukushima Medical University Hospital

    Fukushima, Fukushima, 960-1295, Japan

  • Gifu Municipal Hospital

    Gifu, Gifu, 500-8513, Japan

  • Gunma Prefectural Cancer Center

    Ota-shi, Gunma, 373-8550, Japan

  • Hokkaido Cancer Center

    Sapporo, Hokkaido, 003-0804, Japan

  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital

    Nagoya, Aichi-ken, 466-8650, Japan

  • Japanese Red Cross Nagasaki Genbaku Hospital

    Nagasaki, Nagasaki, 852-8104, Japan

  • Japanese Red Cross Society Himeji Hospital

    Himeji-shi, Hyōgo, 670-8540, Japan

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, 241-8515, Japan

  • Kyushu Cancer Center

    Fukuoka, Fukuoka, 811-1395, Japan

  • Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai

    Osaka, Osaka, 530-0025, Japan

  • Nagoya Medical Center

    Nagoya, Aichi-ken, 460-0001, Japan

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    Kashiwa-shi, Chiba, 277-8577, Japan

  • Osaka Saiseikai Nakatsu Hospital

    Osaka, Osaka, 530-0012, Japan

  • Shimane University Hospital

    Izumo-shi, Shimane, 693-8501, Japan

  • Shinshu University Hospital

    Matsumoto-shi, Nagano, 390-8621, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, 980-8574, Japan

  • Tokyo Metropolitan Komagome Hospital

    Bunkyo-ku, Tokyo, 113-8677, Japan

  • University Hospital, Kyoto Prefectural University of Medicine

    Kyoto, Kyoto, 602-8566, Japan

  • Yamagata University Hospital

    Yamagata, Yamagata, 990-9585, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.